{"id":973959,"date":"2021-11-05T20:29:22","date_gmt":"2021-11-06T00:29:22","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=973959"},"modified":"2021-11-05T20:29:25","modified_gmt":"2021-11-06T00:29:25","slug":"pfizer-announces-promising-results-of-new-covid-pill","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/pfizer-announces-promising-results-of-new-covid-pill\/","title":{"rendered":"Pfizer Announces Promising Results Of New COVID Pill"},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"float:left\"><div class=\"counts mashsbcount\">16<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Fpfizer-announces-promising-results-of-new-covid-pill%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=973959&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><p class=\"p1\">On Friday, drug company Pfizer announced results from an interim analysis reportedly showing its new pill designed to treat COVID-19 minimized the risk of death or hospitalization by 89%.<\/p>\n<p class=\"p1\">In an announcement, the company <a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-novel-covid-19-oral-antiviral-treatment-candidate\">stated<\/a>:<\/p>\n<p>PAXLOVID\u2122 [\u2026]&nbsp;was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19In the overall study population through Day 28, no deaths were reported in patients who received&nbsp;PAXLOVID\u2122&nbsp;as compared to 10 deaths in patients who received placeboPfizer plans to submit the data as part of its ongoing rolling submission to the U.S. [Food and Drug Administration] for Emergency Use Authorization (EUA) as soon as possible<\/p>\n<p class=\"p6\">\u201cToday\u2019s news is a real game-changer in the global efforts to halt the devastation of this pandemic. These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients\u2019 lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,\u201d said Albert Bourla, Chairman and Chief Executive Officer of Pfizer. \u201cGiven the continued global impact of COVID-19, we have remained laser-focused on the science and fulfilling our responsibility to help healthcare systems and institutions around the world while ensuring equitable and broad access to people everywhere.\u201d<\/p>\n<p class=\"p6\">\u201cAll of us at Pfizer are incredibly proud of our scientists, who designed and developed this molecule, working with the utmost urgency to help lessen the impact of this devastating disease on patients and their communities,\u201d said Mikael Dolsten, MD, PhD., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer. \u201cWe\u2019re thankful to all of the patients, investigators, and sites around the world who participated in this clinical trial, all with the common goal of bringing forth a breakthrough oral therapy to help combat COVID-19.\u201d<\/p>\n<p class=\"p1\">As the BBC <a href=\"https:\/\/www.bbc.com\/news\/health-59178291\">reported<\/a>, \u201cThe drug \u2013 Paxlovid \u2013 is intended for use soon after symptoms develop in people at high risk of severe disease.\u201d<\/p>\n<p class=\"p1\">The company also noted that, per \u201cthe recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA),\u201d it ended more enrollment into its study because of \u201cthe overwhelming efficacy demonstrated in these results\u2026\u201d<\/p>\n<p class=\"Text__text___3eVx1j Text__dark-grey___AS2I_p Text__regular___Bh17t- Text__large___1i0u1F Body__base___25kqPt Body__large_body___3g04wK ArticleBody__element___3UrnEs\" data-testid=\"paragraph-1\">On Friday, President Biden <a href=\"https:\/\/www.reuters.com\/world\/us\/biden-says-us-has-secured-doses-new-pfizer-covid-pill-2021-11-05\/\">said<\/a>, \u201cIf authorized by the FDA we may soon have pills that treat the virus in those who become infected,\u201d noting, \u201cWe\u2019ve already secured millions of doses. The therapy would be another tool in our toolbox to protect people from<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On Friday, drug company Pfizer announced results from an interim analysis reportedly showing its new pill designed to treat COVID-19 minimized the risk of death or hospitalization by 89%.In an announcement, the company stated:PAXLOVID\u2122 [\u2026]\u00a0was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19In the overall study population through Day 28, no deaths were reported in patients who received\u00a0PAXLOVID\u2122\u00a0as compared to 10 deaths in patients who received placeboPfizer plans to submit the data as part of its ongoing rolling submission to the U.S. [Food and Drug Administration] for Emergency Use Authorization (EUA) as soon as possible\u201cToday\u2019s news is a real game-changer in the global efforts to halt the devastation of this pandemic. These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients\u2019 lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,\u201d said Albert Bourla, Chairman and Chief Executive Officer of Pfizer. \u201cGiven the continued global impact of COVID-19, we have remained laser-focused on the science and fulfilling our responsibility to help healthcare systems and institutions around the world while ensuring equitable and broad access to people everywhere.\u201d\u201cAll of us at Pfizer are incredibly proud of our scientists, who designed and developed this molecule, working with the utmost urgency to help lessen the impact of this devastating disease on patients and their communities,\u201d said Mikael Dolsten, MD, PhD., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer. \u201cWe\u2019re thankful to all of the patients, investigators, and sites around the world who participated in this clinical trial, all with the common goal of bringing forth a breakthrough oral therapy to help combat COVID-19.\u201dAs the BBC reported, \u201cThe drug \u2013 Paxlovid \u2013 is intended for use soon after symptoms develop in people at high risk of severe disease.\u201dThe company also noted that, per \u201cthe recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA),\u201d it ended more enrollment into its study because of \u201cthe overwhelming efficacy demonstrated in these results\u2026\u201dOn Friday, President Biden said, \u201cIf authorized by the FDA we may soon have pills that treat the virus in those who become infected,\u201d noting, \u201cWe\u2019ve already secured millions of doses. The therapy would be another tool in our toolbox to protect people from the worst outcomes of COVID.\u201dThe BBC reported on Friday, \u201cThe UK has already ordered 250,000 courses of the new Pfizer treatment, which has not yet been approved, along with another 480,000 courses of MSD\u2019s molnupiravir pill.\u201dForbes reported the U.S. \u201chas committed to buying\u00a01.7 million\u00a0courses of molnupiravir if it gets approved by the FDA for emergency use,\u201d as well.Britain became the first country in the world to approve the COVID-19 pill by the company Merck earlier this week.As\u00a0reported\u00a0by Reuters:Britain\u2019s Medicines and Healthcare products Regulatory Agency (MHRA)\u00a0recommended\u00a0the drug, molnupiravir, for use in people with mild to moderate COVID-19 and at least one risk factor for developing severe illness, such as obesity, older age diabetes, and heart disease.\u201cThe pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe disease, such as obesity or heart disease. Patients with mild-to-moderate COVID-19 would take four pills of the drug, known molnupiravir, twice a day for five days,\u201d The Associated Press\u00a0reported.The country is the first in the world to approve use of the drug, which could potentially lead to other nations doing the same.As\u00a0reported\u00a0by The Daily Wire, Merck stated last month that the company, as well as Ridgeback Biotherapeutics, asked for emergency authorization from the U.S. Food and Drug Administration (FDA) for the molnupiravir pill.\u201cMerck has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and\/or hospitalization,\u201d Merck announced in a press release. \u201cThe companies are actively working with regulatory agencies worldwide to submit applications for emergency use or marketing authorization in the coming months.\u201dThe Daily Wire noted that the appeal was based on \u201cpositive results from a planned interim analysis\u201d which \u201cevaluated molnupiravir in non-hospitalized adult patients with mild-to-moderate COVID-19 who were at risk for progressing to severe COVID-19 and\/or hospitalization.\u201d Per the interim analysis, \u201cmolnupiravir reduced the risk of hospitalization or death by approximately 50%.\u201dThe FDA reportedly stated in October that a group of independent specialists would look into the effects and safety of the drug later this month.The Daily Wire is one of America\u2019s fastest-growing conservative media companies and counter-cultural outlets for news, opinion, and entertainment. Get inside access to The Daily Wire by becoming a member.<\/p>\n","protected":false},"author":95,"featured_media":2315279,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[],"tags":[],"class_list":["post-973959","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/973959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/95"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=973959"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/973959\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/2315279"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=973959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=973959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=973959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}